What can be learned from the nda and bla reviews of newly approved drugs? A systematic review of drug interaction data for drugs approved by the US FDA IN 2014

Yu Jingjing; Ritchie Tasha K.; Zhou Zhu; Ragueneau-Majlessi Isabelle

首页> 外文期刊>Drug Metabolism Reviews >What can be learned from the nda and bla reviews of newly approved drugs? A systematic review of drug interaction data for drugs approved by the US FDA IN 2014

【24h】

What can be learned from the nda and bla reviews of newly approved drugs? A systematic review of drug interaction data for drugs approved by the US FDA IN 2014

机译：从新批准药品的NDA和bla审查中可以学到什么？对美国FDA在2014年批准的药物的药物相互作用数据的系统综述

获取原文

获取原文并翻译 | 示例

掌桥外文数据库（机构版） >>

开具论文收录证明 >>

页面导航

著录项
相似文献
相关主题

著录项

来源
《Drug Metabolism Reviews》 |2016年第4期|共1页
作者
Yu Jingjing; Ritchie Tasha K.; Zhou Zhu; Ragueneau-Majlessi Isabelle;
展开▼
作者单位

展开▼
收录信息
原文格式 PDF
正文语种 eng
中图分类药理学;
关键词

相似文献

外文文献
中文文献
专利

1. What can be learned from the nda and bla reviews of newly approved drugs? A systematic review of drug interaction data for drugs approved by the US FDA IN 2014 [J] . Yu Jingjing, Ritchie Tasha K., Zhou Zhu, Drug Metabolism Reviews . 2016,第1a4期

机译：从新批准药品的NDA和bla审查中可以学到什么？对美国FDA在2014年批准的药物的药物相互作用数据的系统综述
2. What can be learned from the nda and bla reviews of newly approved drugs? A systematic review of drug interaction data for drugs approved by the US FDA IN 2014 [J] . Yu Jingjing, Ritchie Tasha K., Zhou Zhu, Drug Metabolism Reviews . 2016,第1a4期

机译：从NDA和BLA评论的新批准药物的评论可以了解到什么？ 2014年美国FDA批准的药物互动数据的系统审查
3. What Can Be Learned from Recent New Drug Applications? A Systematic Review of Drug Interaction Data for Drugs Approved by the US FDA in 2015 [J] . Yu Jingjing, Zhou Zhu, Owens Katie H., Drug Metabolism and Disposition: The Biological Fate of Chemicals . 2017,第1期

机译：最近的新药物应用中可以学到什么？ 2015年美国FDA批准的药物互动数据的系统审查
4. Using Machine Learning to Predict the Binding Dissociation of FDA Approved Drugs for Affinity- Based Drug Delivery Applications [C] . Edgardo Rivera-Delgado, Alison Xin, Horst A. von Recum Society for Biomaterials annual meeting and exposition . 2019

机译：使用机器学习预测基于亲和力的药物递送应用的FDA批准药物的结合解离
5. Molecular Determinants for Binding of the FDA-Approved Drugs in Proteins – A Data Mining and Advanced Quantum Chemical Study [D] . Alqahtani, Saad. 2017

机译：FDA批准的药物与蛋白质结合的分子决定因素–数据挖掘和先进的量子化学研究
6. Cutaneous Adverse Events in Newly Approved FDA Non-cancer Drugs: A Systematic Review [O] . Paul C. Macklis, Brittany Dulmage, Brady Evans, 2020

机译：新批准的FDA非癌症药物中的皮肤不良事件：系统审查
7. What Can Be Learned from Recent New Drug Applications? A Systematic Review of Drug Interaction Data for Drugs Approved by the US FDA in 2015 [O] . Jingjing Yu, Zhu Zhou, Katie H. Owens, 2016

机译：最近的新药物应用中可以学到什么？ 2015年美国FDA批准的药物互动数据的系统审查
8. Guidance for FDA Staff and Industry: Marketed Unapproved Drugs. Compliance Policy Guide. Sec. 440.100 Marketed New Drugs Without Approved NDAs or ANDAs (September 19, 2011) [R] . 2011

机译：FDa工作人员和行业指南：未经批准的未经批准的药物。合规政策指南。秒。 440.100未经批准的NDa或aNDa上市的新药（2011年9月19日）

What can be learned from the nda and bla reviews of newly approved drugs? A systematic review of drug interaction data for drugs approved by the US FDA IN 2014

著录项

相似文献

相关主题

期刊订阅